PhaseBio Pharmaceuticals Debt to Equity

PhaseBio Pharmaceuticals (PHAS) currently reports a debt-to-equity ratio of -0.06. That is below the Healthcare sector average of 0.93. Use the charts on this page to explore PhaseBio Pharmaceuticals's debt-to-equity ratio history and peer comparisons.

PhaseBio Pharmaceuticals's debt-to-equity ratio of -0.06 is lower than the Healthcare sector average of 0.93. That is roughly 106.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates PhaseBio Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -0.06, PHAS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of -0.06, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.93. From there, open related valuation or income-statement pages for PhaseBio Pharmaceuticals, and consider following PHAS for alerts when major investors trade the stock.

PhaseBio Pharmaceuticals is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -0.06 versus a sector average near 0.93. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAS with unrelated industries.